Reguleren of neutraliseren van anticoagulantia

Reversal of antithrombotic agents. (opent nieuw venster)

Bauer KA.

Bron‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Geïndexeerd‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (opent nieuw venster)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (opent nieuw venster)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Bron‎: J Thromb Haemost 2015;13(10):1790-8.

Geïndexeerd‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (opent nieuw venster)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (opent nieuw venster)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Bron‎: N Engl J Med 2019;380(14):1326-35.

Geïndexeerd‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (opent nieuw venster)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (opent nieuw venster)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Bron‎: N Engl J Med 2016;375(12):1131-41.

Geïndexeerd‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (opent nieuw venster)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (opent nieuw venster)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Bron‎: Circulation 2011;124(14):1573-9.

Geïndexeerd‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (opent nieuw venster)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (opent nieuw venster)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Bron‎: Lancet 2015;385(9982):2077-87.

Geïndexeerd‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (opent nieuw venster)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (opent nieuw venster)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Bron‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Geïndexeerd‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (opent nieuw venster)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (opent nieuw venster)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Bron‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Geïndexeerd‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (opent nieuw venster)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (opent nieuw venster)

Levi M, Eerenberg E, Kamphuisen PW.

Bron‎: J Thromb Haemost 2011;9(9):1705-12.

Geïndexeerd‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (opent nieuw venster)

Emergency reversal of warfarin anticoagulation. (opent nieuw venster)

Lin Y, Callum J.

Bron‎: CMAJ 2010;182(18):2004.

Geïndexeerd‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (opent nieuw venster)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (opent nieuw venster)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Bron‎: Thromb Haemost 2012;108(2):217-24.

Geïndexeerd‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (opent nieuw venster)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (opent nieuw venster)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Bron‎: J Thromb Haemost 2008;6(4):622-31.

Geïndexeerd‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (opent nieuw venster)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (opent nieuw venster)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Bron‎: Blood Adv 2019;3(2):158-67.

Geïndexeerd‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (opent nieuw venster)

Idarucizumab for dabigatran reversal. (opent nieuw venster)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Bron‎: N Engl J Med 2015;373(6):511-20.

Geïndexeerd‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (opent nieuw venster)

Idarucizumab for dabigatran reversal - full cohort analysis. (opent nieuw venster)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Bron‎: N Engl J Med 2017;377(5):431-41.

Geïndexeerd‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (opent nieuw venster)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (opent nieuw venster)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Bron‎: Blood 2003;102(13):4594-9.

Geïndexeerd‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (opent nieuw venster)

Role of agents for reversing the effects of target-specific oral anticoagulants. (opent nieuw venster)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Bron‎: Am J Health Syst Pharm 2017;74(2):54-61.

Geïndexeerd‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (opent nieuw venster)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (opent nieuw venster)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Bron‎: Anesth Analg 2011;113(4):703-10.

Geïndexeerd‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (opent nieuw venster)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (opent nieuw venster)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Bron‎: J Am Coll Cardiol 2017;70(24):3042-67.

Geïndexeerd‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (opent nieuw venster)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (opent nieuw venster)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Bron‎: World Neurosurg 2014;81(1):110-5.

Geïndexeerd‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (opent nieuw venster)

Reversal of warfarin-induced hemorrhage in the emergency department. (opent nieuw venster)

Zareh M, Davis A, Henderson S.

Bron‎: West J Emerg Med 2011;12(4):386-92.

Geïndexeerd‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (opent nieuw venster)

INTENSIVE CARE

Reguleren of neutraliseren van anticoagulantia

Nederlands

Reguleren of neutraliseren van anticoagulantia

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Reguleren of neutraliseren van anticoagulantia

Reversal of antithrombotic agents. (opent nieuw venster)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (opent nieuw venster)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (opent nieuw venster)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (opent nieuw venster)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (opent nieuw venster)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (opent nieuw venster)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (opent nieuw venster)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (opent nieuw venster)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (opent nieuw venster)

Emergency reversal of warfarin anticoagulation. (opent nieuw venster)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (opent nieuw venster)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (opent nieuw venster)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (opent nieuw venster)

Idarucizumab for dabigatran reversal. (opent nieuw venster)

Idarucizumab for dabigatran reversal - full cohort analysis. (opent nieuw venster)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (opent nieuw venster)

Role of agents for reversing the effects of target-specific oral anticoagulants. (opent nieuw venster)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (opent nieuw venster)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (opent nieuw venster)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (opent nieuw venster)

Reversal of warfarin-induced hemorrhage in the emergency department. (opent nieuw venster)

Contact met lokale vertegenwoordiger van het ziekenhuiscontactcomité

Medische informatiepakketten

Video’s

Reguleren of neutraliseren van anticoagulantia

Selecteer een taal

Delen